New hope for advanced cancers: first human trial launches
NCT ID NCT05306132
First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-stage study tests a new drug, ASKC202, alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 150 adults will take part in this first-in-human trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital Affiliated to Tongji University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hunan, China
Contact
Conditions
Explore the condition pages connected to this study.